Sanofi's Five Q1 Approvals Signal GMP Capacity Pressure Ahead

Sanofi enters the second quarter of 2026 carrying five new regulatory approvals, all in immunology, alongside a completed acquisition and a pharma launches segment that grew 49.6% year-on-year. For plant heads and QA directors, that combination translates directly into near-term pressure on manufacturing capacity, supply chain qualification, and GMP compliance infrastructure across multiple product lines simultaneously.

Net sales reached €10.5 billion in Q1 2026, a 13.6% increase at constant exchange rates (CER). Dupixent drove the headline figure, posting €4.2 billion in quarterly sales, up 30.8%. Pharma launches sales reached €1.2 billion, led by Ayvakit, ALTUVIIIO, and Sarclisa. Vaccines contributed €1.3 billion, up 2.1%, with Heplisav-B cited as a key driver. Selling and general expenses rose 11.6% to €2.3 billion, with Sanofi attributing the increase primarily to the effect of recent acquisitions, including the now-completed Dynavax transaction.

The pipeline picture adds further compliance and operational complexity. Two regulatory submission acceptances, one Phase 3 study start, and four regulatory designations, including breakthrough and orphan status, were recorded in the quarter. Positive Phase 3 data for venglustat in the rare disease GD3 and Phase 2 data for lunsekimig in respiratory diseases indicate additional submissions are likely within planning horizons relevant to process validation and tech transfer teams. Separately, a positive CHMP recommendation for acoziborole, a single-dose oral treatment for sleeping sickness co-developed with DNDi under a 25-year WHO partnership, adds a neglected disease programme to the near-term regulatory docket.

Research and development expenses reached €1.7 billion, up 1.5%, while business EPS came in at €1.88, up 14.0% at CER. Sanofi affirmed full-year 2026 guidance of high single-digit sales growth at CER, with business EPS expected to grow slightly faster than sales. Interim CEO Olivier Charmeil noted total operating expenses grew at a measured 7.0%, a figure regulatory affairs and operations leads will weigh against the resource demands of managing five concurrent post-approval compliance obligations. Belén Garijo is expected to assume the CEO role next month.